Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017)

Chamberlain C.; Colman P. J.; Ranger A. M.; Burkly L. C.; Johnston G. I; Otoul C.; Stach C.; Zamacona M.; Dorner T.; Urowitz M.; Hiepe F.

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017)

【24h】

Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017)

机译：重复施用Dapirolizuab PEGOL在随机阶段I研究中的研究是良好的耐受性，并伴随着几种系统性红斑狼疮疾病活性的综合措施的改进，以及全血转录组分的变化（Vol 77，PG 1837,2017）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research 》 |2018年第5期| 共2页
作者
Chamberlain C.; Colman P. J.; Ranger A. M.; Burkly L. C.; Johnston G. I; Otoul C.; Stach C.; Zamacona M.; Dorner T.; Urowitz M.; Hiepe F.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病 ;
关键词

相似文献

外文文献

1. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017) [J] . Chamberlain C., Colman P. J., Ranger A. M., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018 ,第5期

机译：重复施用Dapirolizuab PEGOL在随机阶段I研究中的研究是良好的耐受性，并伴随着几种系统性红斑狼疮疾病活性的综合措施的改进，以及全血转录组分的变化（Vol 77，PG 1837,2017）
2. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. [J] . Merrill JT, Wallace DJ, Petri M, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2011 ,第11期

机译：sifalimumab（一种完全人源抗干扰素α单克隆抗体）在系统性红斑狼疮中的安全性和临床活性：I期，多中心，双盲随机研究。
3. Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus (vol 69, pg 124, 2017) [J] . George, Wong-Pack Andrew Arthritis care & research . 2017 ,第3期

机译：教育对疾病活性和血腥红斑狼疮损伤的影响：狼疮1000个加拿大面脸的数据（Vol 69，PG 124,2017）
4. Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study [O] . Lieh-bang Liou, Che-ching Huang -1

机译：全身性红斑狼疮和类风湿关节炎患者外周血B细胞中唾液酸转移酶和神经氨酸酶水平/比率和唾液酸水平与疾病活动性的相关性：一项初步研究
5. FRI0195 EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY [O] . Richard Furie, Ian N. Bruce, Thomas Dörner, 2019

机译：Dapirolizumab Pegol（DZP）在适度到严重活跃的全身性狼疮（SLE）的患者中的疗效和安全性（SLE）：随机，安慰剂（PBO） - 控制研究

Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017)

著录项

相似文献

相关主题

期刊订阅